Research programme: recombinant protein anti-inflammatories - Ablynx/LabGenius
Latest Information Update: 04 Aug 2021
At a glance
- Originator Ablynx; LabGenius
- Class Anti-inflammatories; Immunoglobulin fragments; Recombinant proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation